BRAF is a therapeutic target in aggressive thyroid carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• BRAF oncogenic mutations are prevalent in papillary (44%) and anaplastic (24%) thyroid carcinomas.
• BRAF mutations are linked to poorer clinical outcomes in papillary thyroid carcinoma.
• BRAF represents a potential therapeutic target for thyroid malignancies.

Purpose of the Study:

• To investigate the therapeutic potential of targeting BRAF in thyroid carcinoma.
• To evaluate the efficacy of BRAF inhibition in preclinical models of thyroid cancer.

Main Methods:

• RNA interference was used to knock down BRAF in anaplastic thyroid carcinoma cell lines (FRO, ARO) with BRAF V600E mutation.
• A multikinase inhibitor, BAY 43-9006, was used to inhibit RAF family kinases in BRAF-positive thyroid carcinoma cell lines and xenografts.
• Effects were assessed on cell proliferation, mitogen-activated protein kinase (MAPK) signaling, and tumor growth in mice.

Main Results:

• BRAF knockdown significantly inhibited MAPK signaling and growth of ARO and FRO cells (P < 0.0001).
• BAY 43-9006 treatment mimicked these effects in thyroid carcinoma cells (IC50 = 0.5-1 µmol/L; P < 0.0001) with minimal impact on normal thyrocytes.
• BAY 43-9006 significantly reduced ARO cell xenograft tumor size in mice (P < 0.0001), associated with suppressed phospho-MAPK levels.

Conclusions:

• BRAF signaling is critical for the proliferation of thyroid carcinoma cells harboring the V600E mutation.
• BRAF suppression demonstrates therapeutic potential for BRAF-positive thyroid cancers.
• Targeting BRAF offers a promising strategy for treating specific thyroid carcinoma subtypes.